Minocycline Topical Foam to be Available in Pharmacies Starting January 13
In October 2019, minocycline was the first topical foam to be approved by the FDA for any condition. The once-daily therapy will be available in retail, community, and specialty pharmacies, according to Foamix.
Minocycline topical foam, 4% (Amzeeq, Foamix) will be available by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients age 9 years or older, starting January 13.
In October 2019, minocycline was the first topical foam to be approved by the FDA for any condition. The once-daily therapy will be available in retail, community, and specialty pharmacies, according to Foamix.
Minocycline has not been previously available as a topical treatment due to its instability in traditional topical formulations. By using proprietary Molecule Stabilizing Technology, Foamix has been able to effectively deliver minocycline in a foam-based vehicle that maintains the stability of the active ingredient while delivering it directly on the skin, according to the company.
A broad range of digital consumer outreach tactics have been implemented for this product, such as a unique unboxing-style “how to use” video to help patients easily understand the product.
RELATEDARTICLE
FDA Approves Minocycline Topical Foam for Acne Vulgaris
REFERENCE
Foamix announces AMZEEQ (minocycline) topical foam available in pharmacies nationwide on January 13thfor the treatment of moderate to severe acne [news release]. Rehovot, Israel and Bridgewater, NJ; PR Newswire: January 9, 2020. https://prnmedia.prnewswire.com/news-releases/foamix-announces-amzeeq-minocycline-topical-foam-available-in-pharmacies-nationwide-on-january-13th-for-the-treatment-of-moderate-to-severe-acne-300984107.html. Accessed January 9, 2020.
